Search results
Showing 106 to 120 of 199 results for advanced breast cancer
This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013
Discontinued Reference number: GID-TA11318
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
In development Reference number: GID-TA11862 Expected publication date: TBC
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued Reference number: GID-TA10570
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
Awaiting development Reference number: GID-TA11723 Expected publication date: TBC
Discontinued Reference number: GID-TAG432
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
In development Reference number: GID-TA11535 Expected publication date: TBC
Discontinued Reference number: GID-TAG436
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.
Show all sections
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
Discontinued Reference number: GID-TAG417